443912-70-7

Basic information

• Product Name: 2H-Pyran-4-carboxylicacid,tetrahydro-4-methyl-,methylester(9CI)
• Synonyms: 2H-Pyran-4-carboxylicacid,tetrahydro-4-methyl-,methylester(9CI);4-Methyltetrahydropyran-4-carboxylic acid methyl ester;Tetrahydro-4-methyl-2H-pyran-4-carboxylic acid methyl ester;Methyl 4-Methyltetrahydro-2H-pyran-4-carboxylate;Methyl 4-Methyltetrahydro...;Methyl 4-Methyloxane-4-carboxylate;methyl tetrahydro-4-methyl-2H-pyran-4-carboxylate
• CAS NO: 443912-70-7
• Molecular Formula: C8H14O3
• Molecular Weight: 158.196
• Product Categories: CARBOXYLICESTER
• Mol File: 443912-70-7.mol

Chemical Properties

• Boiling Point: 195℃
• Flash Point: 72℃
• Appearance: /
• Density: 1.030
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2H-Pyran-4-carboxylicacid,tetrahydro-4-methyl-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Pyran-4-carboxylicacid,tetrahydro-4-methyl-,methylester(9CI)(443912-70-7)
• EPA Substance Registry System: 2H-Pyran-4-carboxylicacid,tetrahydro-4-methyl-,methylester(9CI)(443912-70-7)

Safety Data

• Hazardous Substances Data: 443912-70-7(Hazardous Substances Data)

Usage

Uses

Since the provided materials do not offer specific details about the use or biological activity of 2H-Pyran-4-carboxylicacid, tetrahydro-4-methyl-, methylester(9CI), it is not possible to list its applications based on the given information. Further research or data would be required to determine its potential uses in various industries or applications.

Upstream product

• 110238-91-0 tetrahydropyran-4-carboxylic acid methyl ester 
• 74-88-4 methyl iodide 

Downstream Products

• 65626-22-4 4-methyltetrahydro-2H-pyran-4-carbaldehyde 
• 1307304-94-4 C₁₆H₂₂N₂O₂ 
• 1338815-17-0 3-(4-methyltetrahydro-2H-pyran-4-yl)-1-(p-tolyl)-1H-pyrazol-5-amine 
• 1338814-68-8 2-methoxy-N-(4-(4-(3-(3-(4-methyltetrahydro-2H-pyran-4-yl)-1-p-tolyl-1H-pyrazol-5-yl)ureido)naphthalen-1-yloxy)pyridin-2-yl)acetamide 
• 233276-38-5 4-methyltetrahydro-2H-pyran-4-carboxylic acid 
• 502609-47-4 (4-methyltetrahydro-2H-pyran-4-yl)methanol 

Relevant articles and documents

3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

HYDROXYL PURINE COMPOUNDS AND USE THEREOF

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.

Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment o

Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease

The invention relates to novel organic compounds of formula (I), and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.

Modulation on C- and N-terminal moieties of a series of potent and selective linear tachykinin NK2 receptor antagonists

Herein we describe the synthesis of a series of new potent tachykinin NK2 receptor antagonists by the modulation of the Cand N-terminal moieties of ibodutant (MEN 15596, 1). The Nterminal benzo[b]thiophene ring was replaced by different substituted naphthalenes and benzofurans, while further modifications were evaluated at the C-terminal tetrahydropyran moiety. Most compounds demonstrated a high affinity for the human NK2 receptor and high in vitro antagonist potency, indicating that a wide range of substituents at both termini can be incorporated in the molecule without detrimental effects on the interactions with the NK2 receptor. Selected compounds were tested in vivo confirming their activity as NK2 antagonists. In particular, after both iv and id administration to guinea pig, compound 61b was able to antagonize NK2-induced colonic contractions with a potency and duration-of-action fully comparable to the reference compound 1 (MEN 15596, ibodutant).

NOVEL PIPERIDINE/8-AZABICYCLO [3.2.1] OCTAN DERIVATIVES AS MODUILATORS OF CHEMOKINE RECEPTOR CCR5

Compounds of formula (I) wherein neither R4 nor R5 is hydrogen; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).

CHEMICAL COMPOUNDS

Compounds of formula (I): [Chemical formula should be inserted here. Please see paper copy] compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).

REVERSE HYDROXAMIC ACID DERIVATIVES

Reverse hydroxamic acid derivatives having specific structure represented by a general formula (Ia): (wherein A is a hydrogen atom or the like; Ar1 is an arylene or the like; Ar2 is an optionally substituted aryl, a heteroaryl or the